| Autor: |
Meredith S. Irwin, Michael Ohh, Yoshihito Kano, Claire M. Robinson, Gabriella Christopher, Teresa Adderley, Lynn Kee, Yagnesh Ladumor, Ivette Valencia-Sama |
| Rok vydání: |
2023 |
| DOI: |
10.1158/0008-5472.22423409.v1 |
| Popis: |
Figure S1 - Sensitivity of NB cell lines to allosteric SHP2 inhibitors. Figure S2 - Sensitivity of NB cell lines to catalytic SHP2 inhibitors. Figure S3 - Sensitivity to SHP2 inhibitors in isogenic NB cells with exogenous PTPN11 mutations. Figure S4 - NRAS status determines sensitivity to SHP2 and MAPK inhibition. Figure S5 - MAPK inhibitors sensitize NB cells to SHP099 and II-B08. Figure S6 - SHP2 inhibitors are synergistic with trametinib and other MAPK inhibitors. Figure S7 - MAPK inhibitors synergize with SHP2 inhibitors in ALK-mutant NB cells. Figure S8 - Assessment of drug tolerability for SHP099 and trametinib in vivo. Figure S9 - Pre-clinical assessment of SHP099 plus trametinib in NRAS-mutant NB xenografts. Figure S10 - Pre-clinical assessment of SHP099 plus ulixertinib in NRAS-mutant NB xenografts. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
